Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Behind the Study: Evaluations in TRAMP Prostate Cancer Model

Oncotarget

September 20, 2021
Dr. Yves Chabu from the University of Missouri describes a research paper he co-authored in 2020 that was published by Oncotarget, entitled, “Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model.” continue reading »

Oncotarget Testimonial: Dr. Yves Chabu

Oncotarget

September 17, 2021
Dr. Yves Chabu discusses his experience publishing the paper, “Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model,” with Oncotarget. continue reading »

New Study: Nanoparticles Target Acute Myeloid Leukemia

Oncotarget

Author: Kathryn Atkins | Scientific Content Writer | September 15, 2021
Researchers developed a nanoparticle-based T cell engager (nanoTCE) technology believed to be capable of targeting any immune cell and cancer of interest. NanoTCE efficacy was examined in acute myeloid leukemia. continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #19

Oncotarget

September 14, 2021
Read short summaries of the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 19. continue reading »

Behind the Study: EMT, Endothelial Cells & Tumor Growth

Oncotarget

September 13, 2021
Dr. Tapasree Roy Sarkar describes a research paper she co-authored, entitled, "Carcinoma cells that have undergone an epithelial-mesenchymal transition differentiate into endothelial cells and contribute to tumor growth." continue reading »